Newsroom

ePRO Eliminates Barriers to Cancer Research

•
July 26, 2022
A doctor uses a tablet device.

Go Where Your Patients Are: Launch a Successful Bring Your Own Device (BYOD) Study

•
July 20, 2022

Advantages of Using DDC for Your Clinical Studies

•
July 18, 2022

Clinical ink Reveals Disruptive Technologies’ Worth in Clinical Research

•
June 20, 2022

Clinical Ink Hires CCO Chris Crucitti, COO Brian Donahue, VP Bill Barrasso

•
May 4, 2021

Clinical Ink Deploys eCOA Solutions for Industry’s Most-Complex Assessments 500 Unique Scales and Assessments in 82 Languages

•
April 20, 2021

Clinical Ink Adds 16th Concurrent Alzheimer’s Study Supporting 9,000+ Patients Across 25 Countries

•
April 6, 2021

PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data

•
March 22, 2021

Clinical Ink Celebrates 5 Years of Decentralized Trial Experience
Company Joins the Decentralized Trials & Research Alliance

•
December 9, 2020

McKesson Ventures Invests as Clinical Ink Debuts Lunexis ePRO+ Solution
Mixed Modalities Allow Users to Switch Between Smartphones, Tablets, and Web Any Time

•
December 2, 2020

Clinical Ink Announces Its Acquisition by GI Partners
Transaction Accelerates Momentum of eSource Leader

•
August 4, 2020

Clinical Ink Implements COVID-19 Therapy Trial in Three Weeks
Facilitates Earlier Results for Potential Cytokine Storm Treatment

•
June 1, 2020

Clinical Ink Study Assurance Program Waives Millions of Dollars in Change Order Fees for Ongoing Clinical Trials

•
April 28, 2020

Clinical Ink Donates Mobile Devices to Aid in Mental Tele-Health

•
April 13, 2020

Insert HTML text here.

Scroll to Top